Top Premarket Decliners

MT Newswires Live06-17

Ovid Therapeutics (OVID) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints.

Kaival Brands Innovations Group (KAVL) shares fell 35%, paring Friday's rally.

La Rosa Holdings (LRHC) shares retreated 16%, shaving gains from the previous session.

Zapp Electric Vehicles Group (ZAPP) shares were down 11%, extending Friday's losses.

Marinus Pharmaceuticals (MRNS) shares dropped 8% after the company said that a phase 3 trial of intravenous ganaxolone for the treatment of refractory status epilepticus missed one of its co-primary endpoints.

Price: 1.1900, Change: -2.10, Percent Change: -63.83

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444433166?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-17 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444433166","market":"nz","top_or_hot":-1,"title":"Top Premarket Decliners","media":"MT Newswires Live","content":"<html><body><p> Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (OVID) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints.</p><p>Kaival Brands Innovations Group (KAVL) shares fell 35%, paring Friday's rally.</p><p>La Rosa Holdings (LRHC) shares retreated 16%, shaving gains from the previous session.</p><p>Zapp Electric Vehicles Group (ZAPP) shares were down 11%, extending Friday's losses.</p><p><a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> (MRNS) shares dropped 8% after the company said that a phase 3 trial of intravenous ganaxolone for the treatment of refractory status epilepticus missed one of its co-primary endpoints.</p><p>Price: 1.1900, Change: -2.10, Percent Change: -63.83</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Premarket Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Premarket Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 20:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ovid Therapeutics (OVID) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNS","symbol_name":"Marinus Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444433166","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444433166","pubTimestamp":1718625744,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ovid Therapeutics  shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints.Kaival Brands Innovations Group  shares fell 35%, paring Friday's rally.La Rosa Holdings  shares retreated 16%, shaving gains from the previous session.Zapp Electric Vehicles Group  shares were down 11%, extending Friday's losses.Marinus Pharmaceuticals  shares dropped 8% after the company said that a phase 3 trial of intravenous ganaxolone for the treatment of refractory status epilepticus missed one of its co-primary endpoints.Price: 1.1900, Change: -2.10, Percent Change: -63.83","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNS":"Marinus Pharmaceuticals","OVID":"Ovid Therapeutics Inc.","BK4091":"摩托车制造商","ZAPP":"Zapp Electric Vehicles Group Ltd","BK4007":"制药","BK4159":"经销商","LRHC":"La Rosa Holdings Corp","BK4079":"房地产服务","KAVL":"Kaival Brands Innovations Group, Inc.","BK4139":"生物科技"},"translate_title":"盘前跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAVL":0.9,"LRHC":0.9,"MRNS":0.9,"OVID":0.9,"ZAPP":0.9},"content_text":"Ovid Therapeutics (OVID) shares slumped 64% Monday premarket after the company said that phase 3 studies conducted by Takeda evaluating Soticlestat in certain types of epilepsy missed their primary endpoints.Kaival Brands Innovations Group (KAVL) shares fell 35%, paring Friday's rally.La Rosa Holdings (LRHC) shares retreated 16%, shaving gains from the previous session.Zapp Electric Vehicles Group (ZAPP) shares were down 11%, extending Friday's losses.Marinus Pharmaceuticals (MRNS) shares dropped 8% after the company said that a phase 3 trial of intravenous ganaxolone for the treatment of refractory status epilepticus missed one of its co-primary endpoints.Price: 1.1900, Change: -2.10, Percent Change: -63.83","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444433166"}